Literature DB >> 9187611

Successful treatment of severe dysrhythmias in infants with respiratory syncytial virus infections: two cases and a literature review.

J A Thomas1, S Raroque, W A Scott, L O Toro-Figueroa, D L Levin.   

Abstract

OBJECTIVES: To describe severe myocardial manifestations in two infants with respiratory syncytial virus infection and to review published literature reporting cardiac involvement in patients with respiratory syncytial virus disease.
DESIGN: Case report and literature review.
SETTING: Tertiary care pediatric intensive care unit (ICU). PATIENTS: Two infants admitted to the pediatric ICU for dysrhythmias and severe myocardial dysfunction and infected with respiratory syncytial virus.
INTERVENTIONS: Conventional cardiovascular, antidysrhythmic, and respiratory support, as well as extracorporeal membrane oxygenation and high-frequency oscillatory ventilation.
MEASUREMENTS AND MAIN RESULTS: Both patients had respiratory syncytial virus infections and clinical evidence of severe myocarditis, with dysrhythmias, cardiomegaly, and cardiogenic shock. Both infants survived their hospitalizations. To our knowledge, these two patients are the first reported cases of myocarditis in infants with respiratory syncytial virus infection.
CONCLUSIONS: Severe myocardial dysfunction and dysrhythmias may accompany respiratory syncytial virus infection in some infants and may be reversible with aggressive supportive therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187611     DOI: 10.1097/00003246-199705000-00027

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

Review 1.  Mechanical cardiopulmonary support in children and young adults: extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices.

Authors:  A C Chang; E D McKenzie
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

2.  Prolonged ECMO support for virus-induced cardiorespiratory failure early after cardiac surgery.

Authors:  V L Vida; M Rubino; G Stellin
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

3.  Fatal coronary artery anomaly presenting as bronchiolitis.

Authors:  Marco Piastra; Giancarlo Polidori; Maria Pia De Carolis; Alessia Tempera; Elena Caresta; Silvia Pulitanò; Antonio Chiaretti; Piero Valentini; Gabriella De Rosa
Journal:  Eur J Pediatr       Date:  2005-05-12       Impact factor: 3.183

4.  Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection.

Authors:  Susanna Esposito; Patrizia Salice; Samantha Bosis; Silvia Ghiglia; Elena Tremolati; Claudia Tagliabue; Laura Gualtieri; Paolo Barbier; Carlotta Galeone; Paola Marchisio; Nicola Principi
Journal:  BMC Infect Dis       Date:  2010-10-24       Impact factor: 3.090

5.  Transaminase levels in ventilated children with respiratory syncytial virus bronchiolitis.

Authors:  Michael Eisenhut; Kentigern Thorburn; Tageldin Ahmed
Journal:  Intensive Care Med       Date:  2004-03-13       Impact factor: 17.440

Review 6.  Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review.

Authors:  Michael Eisenhut
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Respiratory syncytial virus-associated mortality in a healthy 3-year-old child: a case report.

Authors:  A Gavotto; A Ousselin; O Pidoux; P Cathala; V Costes-Martineau; B Rivière; J L Pasquié; P Amedro; C Rambaud; G Cambonie
Journal:  BMC Pediatr       Date:  2019-11-27       Impact factor: 2.125

8.  [Atrial chaotic tachycardia during a respiratory tract infection due to NL63 coronavirus].

Authors:  J Chantreuil; G Favrais; N Soule; Z Maakaroun-Vermesse; A Chaillon; A Chantepie; E Saliba
Journal:  Arch Pediatr       Date:  2013-02-05       Impact factor: 1.180

9.  Right and left ventricular function in hospitalized children with respiratory syncytial virus infection.

Authors:  Thorsten Horter; Britt Nakstad; Omid Ashtari; Anne Lee Solevåg
Journal:  Infect Drug Resist       Date:  2017-11-07       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.